{"id":"W2586480138","doi":"10.1016/s1474-4422(17)30007-8","title":"Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study","year":2017,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":162,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Hospitalier de l’Université de Montréal; Université de Montréal; Hôpital Notre-Dame","funders":"NIH Clinical Center; National Health and Medical Research Council; Canadian Institutes of Health Research; Novartis Pharma; EMD Serono; H. Lundbeck A/S; Sanofi Genzyme; Isfahan University of Medical Sciences; Multiple Sclerosis Society; Celgene; Fondazione Italiana Sclerosi Multipla; Biogen; York University; Università degli Studi di Firenze; Multiple Sclerosis Society of Canada; Univerzita Karlova v Praze; Diabetes-Stiftung; NYU Langone Medical Center; Jewish General Hospital; National Institute for Health and Care Research; Medical Research Council; Teva Pharmaceutical Industries; GlaxoSmithKline; Rosetrees Trust; Sanofi","keywords":"Natalizumab; Fingolimod; Multiple sclerosis; Alemtuzumab; Medicine; Relapsing remitting; Cohort; Interferon beta; Interferon beta-1a; Interferon beta-1b; Internal medicine; Oncology; Immunology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00431419,0.001436851,0.002187609,0.0006575048,0.0006739062,0.001518704,0.001268775,0.001931346,0.001724964],"category_scores_gemma":[0.008406043,0.0009967653,0.004892212,0.001068683,0.0006376745,0.001232156,0.0006462806,0.001889492,0.0003735363],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009593483,"about_ca_system_score_gemma":0.0008376294,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004580573,"about_ca_topic_score_gemma":0.00307887,"domain_scores_codex":[0.9968622,0.001477249,0.0003282322,0.0007363692,0.0002827408,0.0003133164],"domain_scores_gemma":[0.9951315,0.001359239,0.001826061,0.0008548053,0.0003022952,0.0005261288],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5299883,0.004530221,0.391079,0.0005555068,0.05332188,0.0004933442,0.0004766893,0.0007708139,0.00419879,0.0001293065,0.001000764,0.01345537],"study_design_scores_gemma":[0.06530669,0.04439601,0.8429871,0.0001653248,0.04184762,0.0006095368,0.0005072645,0.001325237,0.001137712,0.0003310524,0.001238766,0.000147778],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99699,0.002220123,0.00004780207,0.00008525038,0.00005037439,0.00003498048,0.0003845045,0.000004883252,0.0001820823],"genre_scores_gemma":[0.9983778,0.0006369688,0.00008493435,0.00009914323,0.00007688254,0.00005160768,0.0004243851,0.000005349995,0.0002429062],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004580573,"threshold_uncertainty_score":0.02281588,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09599620926818118,"score_gpt":0.3348241183615268,"score_spread":0.2388279090933456,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}